Subscribe to our newsletter

Get our monthly newsletter with updates on business and science related activities in Medicon Valley.








Latest news

> PRINT THIS PAGE
   SHARE
Here you will find all news from Medicon Valley

321 events   Page 1 of 33   |   Next page
Feb. 6, 2012
> Zealand Pharma announces 94% growth in revenue in preliminary financial results for the year ended 31 December 2011
Significant growth in revenue, sustained cash position
Feb. 3, 2012
> LEO Pharma Announces That Picato® gel has Been Approved by US FDA for Once-Daily, 2 or 3 day Treatment of Actinic Keratoses
Feb. 1, 2012
> Lundbeck : awarded prize for world-class production
Lundbeck has been awarded a silver medallion - and achieved the best-ever result for a European company - in the prestigious Shingo competition, a global contest that honours outstanding productivity improvements.
Jan. 30, 2012
> LEO Pharma A/S In-Licenses Promising Compound From Virobay Inc. for Oral Treatment of Psoriasis
Jan. 20, 2012
> Dako and Amgen to collaborate in development of a companion diagnostic for an Amgen investigational cancer therapy
Jan. 20, 2012
> Galecto Biotech AB receives its initial financing in a Seed round co-led by Merck Serono Ventures and Novo A/S
Newly formed biotechnology company Galecto Biotech AB will focus its activity on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases
Jan. 19, 2012
> Genmab Announces Progress With DuoBody(TM) Platform
DuoBody-ADC Research Collaboration With Undisclosed Pharma Company
Jan. 18, 2012
> Zealand Pharma Receives EUR 3 Million Milestone Payment
3 Million Received Under the License Agreement for Elsiglutide, a Peptide Drug in Development for the Treatment of Chemotherapy Induced Diarrhea
Jan. 17, 2012
> Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH
Jan. 16, 2012
> MorphoSys and Novozymes Sign Long-Term Alliance on Slonomics® Technology for Industrial Biotechnology Applications
Advanced Protein Engineering Technology will Enable Novozymes to Bring Down Discovery Time and Expand Project Portfolio